Alumis
alumis.com
Actively hiring
Sales & Marketing
Biotechnology
Health Care
Immunology & Inflammation Therapeutics
Prescription Drugs
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$240M
4 rounds on record
Latest round
$40M
Venture round · Jul 2024 · 2 yr ago
Team
174
US Form 5500 (plan participants) · Dec 2024
Hiring now
4
open roles
Backers
6
Foresite Capital, HBM Healthcare Investments
The money's age
Long since its last round
26 months since the last round · hiring slowed
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jul 2024 | $40M | — | SEC Form D |
| Venture round | Mar 2024 | $129.5M | — | SEC Form D |
| Venture round | Mar 2021 | $60M | — | SEC Form D |
| Venture round | Feb 2021 | $10.5M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | ALUMIS INC. | sec |
Founders and leadersfrom filings, registers and the company's site
Martin BablerExecutive Officer, DirectorSEC Form D
John SchroerExecutive OfficerSEC Form D
Derrick RichardsonExecutive OfficerSEC Form D
Mark BradleyExecutive OfficerSEC Form D
Sara KleinExecutive OfficerSEC Form D
David GoldsteinExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Foresite Capital 
HBM Healthcare Investments 
Nextech Invest 
OrbiMed 
venBio Partners 
Westlake BioPartners Similar startupsby what they do, their industry and backers
Committed to developing high-impact and differentiated therapies, with a focus on building a robust autoimmune disease and cancer pipeline…
On a mission to transform the future of autoimmune care. Developing innovative therapies with the potential to redefine the standard of…
SFA Therapeutics is developing a next-generation oral immune tolerance therapy for psoriasis. Our investigational approach is designed to…
Explore Ironwood Pharmaceuticals' commitment to GI health with innovative therapies, patient-focused research, and a vision to improve…
Viridian Therapeutics is leveraging core expertise in antibody discovery to develop optimized treatments for rare autoimmune conditions.
Abivax is a clinical-stage biotechnology company driven to advance human health by regulating the immune response through the power of…
How Alumis hires
Truth index
B 75/100
Ghost roles
0%
Stale roles
100%
Reposted roles
0%
Alumis scores B on the Alion truth index (A is best, E worst), measured over 3 open roles re-checked against its own hiring board: 0% look like ghost listings, 100% have gone stale and 0% are the same role posted again. It measures how much of what this employer publishes turns into a real, finite search - not the employer as a workplace. How the index is computed
News
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population
Alumis Inc.
Read more
Report
Alumis to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing ne...
Read more
Report
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair?
Alumis (ALMS) is back in focus after reporting that envudeucitinib missed primary and secondary endpoints in the Phase 2b LUMUS lupus trial, while a predefined interferon gene signature high subgroup showed stronger clinical responses. That mixed trial re
Read more
Report
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
- LUMUS trial did not meet its primary and secondary endpoints in the overall trial population -- Robust responses in the prespecified subgroup of...
Read more
Report
Alumis and ACELYRIN Announce Amended Merger Agreement
Detailed price information for Alumis Inc (ALMS-Q) from The Globe and Mail including charting and trades.
Read more
Report
Pro access
Upgrade to see all 9 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Salary insights
Compensation ranges based on this company's open jobs
Median
$160k
Typical range
$135k – $185k
Open positions
3
3
Jobs
Senior
100%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 3 | $160k | $135k – $185k |
Highest paying role
Senior Manager, People & Culture Operations
$185k
Normalized to USD per year
People
Martin Babler
Executive Officer, Director
John Schroer
Executive Officer
Derrick Richardson
Executive Officer
Mark Bradley
Executive Officer
Sara Klein
Executive Officer
David Goldstein
Executive Officer
Jorn Drappa
Executive Officer
Roy Hardiman
Executive Officer
June Lee
Executive Officer, Director
Richard Gaster
Director
Zhengbin Yao
Director
Sapna Srivastava
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove
Growth
Hiring Momentum
58/100
Growing
Open positions
4
1 opened / 3 closed in 30 days
Median time-to-fill
142 days
faster than 14% of the market
ATS activity
Every ~6 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Marketing
50% ▲
Operations
50% ▼
Activity Timeline
Added Microsoft Office to stack
Sep 2026
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
South San Francisco
South San Francisco
United States
HQ
South San Francisco
4 open roles 1 posted in 90 days 50% engineering 25% remote 10-50 est. staff $160k Avg Salary
hires for Operations, Science & Research